Introduction
Middle East respiratory syndrome coronavirus (MERSCoV) is a beta coronavirus with an enveloped singlestranded, positive-sense RNA genome [1] encoded by ORF1a, 1ab (by frameshifting), 3, 4a, 4b, 5 and 8b, along with genes for spike (S), envelope (E), matrix (M) and nucleocapsid (N) proteins [2] . Spike is a major viral protein of MERS-CoV that binds dipeptidyl peptidase 4 (DPP 4) to facilitate viral entry. Owing to the distribution of DPP 4 in human endothelial and epithelial cells, MERS-CoV infection in humans causes acute respiratory diseases, such as severe acute respiratory syndrome (SARS) [3] .
MERS-CoV infection is fatal and pandemic. The World Health Organization reported 790 deaths among 2,220 cases (35.6% mortality) from 2012 to May 2018 [4] . To date, MERSCoV has been detected in 24 countries, and associated with high mortality rates [5] . In 2015, an outbreak of MERS-CoV in Korea caused 38 deaths among 186 registered cases [6] .
Given the clinical significance of MERS-CoV infection and disease, the need for preventive vaccines and curative treatments remains an urgent unmet medical issue. While a number of attempts have been made, further research is essential to develop effective MERS-CoV vaccines that induce high titers of neutralizing antibodies.
One of the strategies used to design subunit vaccines with enhanced immunogenicity is linkage with the IgG Fc domain based on previous reports that genetic fusion of this domain to vaccine antigens promotes antibody induction and neutralizing activity [7, 8] in addition to altering antigen pharmacokinetics. Decreased renal clearance by the antigen due to dimerization by the Fc domain has been reported [9] . Extended half-life has been demonstrated through interactions with a neonatal Fc receptor (FcRn) [10] .
Here, we constructed a MERS-CoV spike protein, eS770, both without and in combination with human IgG4 Fc (eS770-Fc), with a view to examining the effect of the Fc fusion on folding and immunogenicity of the MERS-CoV subunit vaccine antigen.
Materials and Methods

Cells
Sf9 cells were cultured in SF-900 II medium (Gibco, Waltham, Massachusetts, USA) containing 1% antibiotic-antimycotic solution (Gibco) at 27 
Animals
Female BALB/c mice (6 weeks old) (Orient-Bio, Korea) were provided water and fed ad libitum in the animal facility at the College of Animal Bioscience and Technology, Konkuk University. Experimental procedures were approved by the Konkuk University Institutional Animal Care and Use Committee (IACUC Approval No: KU17021).
Construction of Plasmid DNA Encoding eS770-Fc
For generation of plasmid DNA encoding eS770-Fc, the MERSCoV spike partial gene was genetically fused to the human IgG4 Fc domain through the Gly/Pro linker. The Fc-fused spike partial gene was linked to a baculovirus gp64 signal sequence for expression of the fusion protein outside the cell under control of the polyhedrin promoter (P P H ) of pFastBac 1 vector. All gene constructs used in the cloning procedure were approved by Korea Centers for Disease Control Prevention (Approval No: 16-RDM-008) and custom-synthesized by Bioneer Ltd. (Korea). All the synthesized genes were confirmed via restriction enzyme digestion and sequencing.
Preparation and Amplification of Recombinant Baculovirus Encoding eS770-Fc
To prepare recombinant baculovirus (rBV) expressing the above plasmid constructs, recombinant Bacmid was generated using the Bac-to-Bac Expression System (Invitrogen, USA) and transfected into Sf9 cells using Cellfectin II reagent (Gibco). The supernatant containing rBV was harvested three days after transfection and used as P0 viral stock for infection (0.01 MOI) into static T-flasks (25 cm 2 (P1) or 75 cm 2 (P2)) and roller bottles (P3). Three days after infection, cells were harvested via centrifugation at 6,760 ×g for 10 min and the supernatant used as seed virus. Virus titer was measured using the BakPak Baculovirus Rapid Titer Kit (Clontech, Mountain View, USA).
Expression and Characterization of eS770-Fc
Recombinant proteins were expressed using the baculovirus/ insect cell expression system. In brief, the High Five cell line was infected with three multiplicity of infection (MOI) of rBVs (Ac eS770-Fc). The supernatant was harvested 72 h after infection and centrifuged at 6,760 xg for 10 min. The harvested eS770-Fc protein was equilibrated using buffer (100 mM sodium phosphate, 1.5 M NaCl, pH 8.0) and centrifuged at 18,800 ×g for 20 min. The resulting supernatant was collected and run through a protein A agarose affinity chromatography column (Thermo Fisher, USA) for purification of recombinant protein (eS770-Fc). Concentrated and purified eS770-Fc protein was confirmed via Coomassie blue staining and western blot using a goat anti-MERS Spike antibody (SICGEN, Portugal). Band density was analyzed using MultiGauge Software (Fuji Photo Film Co. Ltd., Japan).
Size Exclusion Chromatography (SEC)
The eS770-Fc protein obtained via protein A affinity chromatography was further purified using SEC. In brief, the protein (1.2 mg/ml) was loaded on a Superose 6 10/300 GL prepacked column (GE Healthcare, Chicago, Illinois, USA) under a flow rate of 0.5 ml/min. Absorbance of the eluting protein was spectrophotometrically measured at 280 nm and purity of the elution fraction determined via SDS-PAGE. Purified recombinant proteins were stored at −80 o C until use.
Preparation of eS770 Lacking Fc
For preparing eS770 devoid of Fc (eS770-ΔFc), eS770-Fc was treated with IdeS protease (Promega, USA) at 37 o C for 1 h for cleavage of the IgG Fc domain. The eS770-ΔFc was purified through a protein A agarose affinity chromatography. The Fc part of the protein or uncut eS770-Fc were removed using a protein A agarose, and the unbound eS770-ΔFc was harvested. For the animal experiment, the eluted eS770-ΔFc was concentrated using Vivaspin Turbo 15 (Germany). In other experiments, eS770 without Fc was prepared by fusion to a histidine tag (eS770-His). The eS770-His protein was expressed in High Five cells and purified using TALON Metal Affinity Resin (Clontech, USA).
Mouse Immunization
Three groups of six-week-old female SPF BALB/c mice (5 per group) were immunized with PBS (G1), 1 μg of each recombinant protein eS770-Fc (G2) or eS770-∆Fc (G3) with alum adjuvant (Thermo Fisher). Immunization was performed intramuscularly with two-week intervals. Blood samples were collected from mouse cheek 10 days after each immunization (days 10 and 24).
Enzyme-Linked Immunosorbent Assay (ELISA)
Indirect ELISA was used to determine the levels of serum antibodies specific for MERS-CoV spike protein. . Absorbance at 450 nm was measured using a microplate reader (BioTek, USA) and the results expressed as reciprocal numbers of the final detectable dilution.
Neutralization Assay with Pseudotype Virus (PV)
MERS-CoV pseudotyped virus was prepared for the neutralization assay as reported previously [11] . The pcDNA3.1 (+)-MERS Spike construct was provided by Dr. Shibo Jiang of Fudan University (China). pNL4-3 Luc R-E-and pcDNA3.1(+)-MERS spike were co-transfected to 293T cells using iN-fect in vitro transfection reagent (iNtRON, Korea). Expression of PV was confirmed via western blot. After infection of Huh7 cells with PV, titration was performed using the luciferase assay.
For the luciferase-based neutralization assay, blood samples were initially incubated at 56 o C for 30 min for complement heat inactivation, followed by two-fold serial dilution (1:40 to 1:20480) using serum-free DMEM. Pseudovirus-containing media (5 × 10 3 RLU/50 μl) were incubated with diluted serum (50 μl) at 37°C for 1 h before adding to Huh 7 cell in 96-well culture plates. After incubation at 37 o C for 48 h, the supernatant was removed and washed three times with PBS. Relative light unit (RLU) was measured using Beetle Lysis-Juice (PJK GmbH, Cat No. 102512) and a Luminescence Counter (PerkinElmer, USA) according to the manufacturer's instructions. The measured RLU is calculated by the following equation to obtain the neutralizing activity.
The neutralizing antibody titer was determined as a dilution factor of the antibody until ≥50% decrease in RLU.
Statistical Analysis
All statistical analyses were performed using GraphPad 7.0 software (USA) and data presented as means ± standard error of mean (SEM). For analysis of the statistical significance of differences, one-way or two-way analysis of variance (ANOVA) was applied. P values ≤0.05 were considered statistically significant.
Results
Expression and Characterization of Recombinant Protein eS770 with or without Fc
To determine the effects of Fc fusion, we generated MERS-CoV partial spike protein constructs with or without the Fc region. Part of the spike protein was synthesized Neutralizing activity 100 RLU of serum sample RLU of control with receptor binding domain that was codon-optimized in insect cells. Human IgG4 Fc domain was fused to a Gly/ Pro linker and the MERS signal sequence replaced with the baculovirus gp64 signal sequence (Fig. 1A) . For baculovirus/ insect cell expression of eS770-Fc, Sf9 cells were transfected with the generated recombinant bacmid. High Five cells were infected with recombinant baculovirus and the secreted recombinant eS770-Fc purified. To prepare eS770 lacking Fc, the Fc region was enzymatically removed as illustrated in (Fig. 1B) . Expression of recombinant protein was detected via SDS-PAGE and Coomassie brilliant blue staining as well as western blot. In Coomassie staining, Unlike lines 1 and 2, line 3 is eS770-∆Fc after IdeS protease treatment. As is shown, IdeS did not completely cleave the protein, so eS770 monomer and undigested eS770-Fc proteins appeared together (Fig. 1C) .
Western blot confirmed the presence of eS770 protein in both eS770-Fc and eS770-∆Fc samples. A major band was detected in the molecular weight region of the eS770 monomer (Fig. 1D) . We further compared western blot (Fig. 1D) and Coomassie brilliant blue staining (Fig. 1C) band densities using Multi-gauge software (Fuji Photo Film Co. Ltd., Japan). In the case of eS770-Fc, a weaker band was detected in the western blot than Coomassie stain (Coomassie blue 72.9: western blot 39.8) while for the eS770 monomer band of eS770-∆Fc, a relatively strong band on the western blot (Coomassie blue 47.78: western blot 74.31) was observed.
Effect of Fc Fusion on Induction of Spike Protein-Specific IgG Antibody
To determine the effects of Fc fusion on immunogenicity, mice were immunized with eS770-Fc, eS770-∆Fc or PBS. Immunization and sample collection schedules are presented in Fig. 2A and injection route, dose and adjuvant in Fig. 2B . In the PBS treatment group, spike proteinspecific IgG antibody in serum was not detected. In groups treated with eS770-Fc and eS770-∆Fc, spike protein-specific IgG antibody titers were increased more than an order of magnitude at 24 days after the first immunization, compared to that at 10 days post-immunization (Fig. 2C) . Notably, however, the eS770-∆Fc treatment group showed significantly greater titers of spike protein-specific IgG antibody, compared with the eS770-Fc treatment group.
Effect of Fc Fusion on Induction of Neutralizing Antibody
Next, we examined whether the fusion with Fc negatively affects induction of the neutralizing antibody using MERS PV to perform the neutralization assay. In vaccine studies, virus-neutralizing antibody measurement is a very important indicator. To do this, live MERS-CoV should be used to test for neutralizing antibody activity in the BL3 facility. However, MERS-CoV pseudotyped virus was constructed for simple and safe neutralizing antibody measurement in the BL2 facility. Fusion with Fc clearly affected the efficacy of induction of the neutralizing antibody. In the group treated with eS770-Fc, negligible neutralizing antibody was detectable, with an average neutralization titer of 40. In contrast, eS770-∆Fc induced neutralizing antibody in 100% mice with an average neutralization titer of 896, signifying >20-fold increase (Fig. 3A) .
To ascertain whether Fc deletion contributes to alterations in the neutralizing antibody response, we additionally constructed eS770-His using a baculovirus expression system. Consistent with data obtained using eS770-∆Fc, eS770-His induced neutralizing antibody in 100% mice. Moreover, immunization with eS770-His resulted in an average neutralization titer of 1920, indicating a 48-fold increase relative to the group immunized with eS770-Fc (Fig. 3B) .
Effect of Fc Fusion on eS770 Protein Aggregation
Fusion with Fc affected physicochemical aggregation of the expressed protein. The SEC elution profiles disclosed notable protein aggregation of eS770-Fc while eS770-His showed notably lower aggregation in SEC and higher concentrations of protein in the later fractions with elution volumes of 23 to 26 ml (Fig. 4A) . SDS-PAGE analysis of the later elution fractions of eS770-His disclosed the presence of a~90 kDa band while eS770-Fc displayed a band with a molecular weight of ~110 kDa (Fig. 4B ).
Discussion
Our collective results suggest that genetic fusion with the IgG Fc region lowers the immunogenicity of MERS-CoV spike protein antigen. Fusion with Fc clearly hindered induction of MERS-CoV spike protein-specific serum IgG as well as neutralizing antibody against MERS PV.
The reduced immunogenicity of eS770 induced by fusion with Fc may be related to structural conformation changes or a formulation problem. In eS770-Fc, the presence of the Fc moiety may contribute to multimer formation, leading to aggregation. As predicted, aggregate formation was observed in the SEC elution profile of eS770-Fc (Fig. 4A) . In contrast to eS770-Fc, eS770-His did not form significant aggregates and showed a distinct structural peak.
The structural conformation of eS770 is crucial for the induction of immunogenicity. Previous studies have reported that MERS-CoV spike protein structurally exists as a trimer in the native state [12] while the Fc fusion protein is in a dimeric form [13] . In SEC elution profiles, the eS770-His peak was observed slightly earlier than the eS770-Fc peak, indicating a larger size of His-bound protein than eS770-Fc in the native form. If the eS770-Fc protein forms a trimer similar to a general spike protein, a larger-sized peak should be detected relative to the eS770-His protein. However, based on the elution profile of eS770-Fc at later fractions, signifying smaller sizes, we assumed that the protein forms a dimer rather than a trimer, resulting in lower immunogenicity. Another way to determine effects on immunogenicity is to compare Coomassie brilliant blue staining and western blot results (Figs. 1C and 1D ). In the case of eS770-Fc, the band from the western blot was weaker than the Coomassie blue stain while that of the eS770 monomer appeared relatively stronger than the Coomassie blue band. In view of these findings, we assume that the antibody binding capacity of eS770-Fc is hindered by Fc fusion to the spike protein.
We compared the effects of Fc-fused MERS-CoV spike protein with those of spike protein lacking the Fc region. In contrast to numerous reports of enhanced immunogenicity of Fc fusion in the design of vaccine antigens, our data show that non-Fc protein vaccine induces an even more potent immune response than Fc-fused vaccine, highlighting the importance of structural analysis after fusion with Fc. The alterations in structural conformation upon fusion with Fc should therefore be evaluated in advance of immunogenicity. According to paper 'MERSCoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015', the titers of neutralization antibody were from 10 to 320. Other MERS-CoV vaccine papers showed that the neutralization titer is usually 320 -1280, which protect the MERS-CoV challenge [11, 14, 15] . Our neutralizing antibody data showed that eS770-∆Fc and eS770-His immunized group induced neutralization titer of 896 and 1920, respectively. These neutralization titers are enough to protect from MERS-CoV infection. In addition, It requires animal experiments using hDPP4-Tg mouse model to evaluate the actual protection ability of the recombinant MERS-CoV S protein (eS770-Fc, eS770-ΔFc eS770-His) vaccine against MERS-CoV in further study. Our findings provide insights that may aid in improving the design of Fc fusion vaccines in the future.
